Literature DB >> 12493150

Osteoporosis in women with breast cancer.

Betty A Mincey1.   

Abstract

Osteoporosis is a disease that causes substantial morbidity and mortality for which preventive therapy is available. Women with breast cancer are at increased risk for osteoporosis for several reasons, including premature ovarian failure as a result of treatment, direct effects of chemotherapy, and effects of the breast cancer itself. As the incidence of breast cancer continues to increase and survival rates continue to improve, the importance of appropriate screening for and management of osteoporosis becomes more apparent. This article reviews the evidence supporting an increased risk for development of osteoporosis in women with breast cancer and summarizes strategies for prevention and treatment of osteoporosis in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493150     DOI: 10.1007/s11912-003-0086-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  26 in total

1.  American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.

Authors: 
Journal:  Endocr Pract       Date:  2001 Jul-Aug       Impact factor: 3.443

2.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.

Authors:  T J Powles; E McCloskey; A H Paterson; S Ashley; V A Tidy; A Nevantaus; K Rosenqvist; J Kanis
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

3.  Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Authors:  P Ravn; M Bidstrup; R D Wasnich; J W Davis; M R McClung; A Balske; C Coupland; O Sahota; A Kaur; M Daley; G Cizza
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

Review 4.  Osteoporosis due to cancer treatment: pathogenesis and management.

Authors:  J Pfeilschifter; I J Diel
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

6.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women.

Authors:  G P Dalsky; K S Stocke; A A Ehsani; E Slatopolsky; W C Lee; S J Birge
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

8.  Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group.

Authors:  E W Gregg; J A Cauley; D G Seeley; K E Ensrud; D C Bauer
Journal:  Ann Intern Med       Date:  1998-07-15       Impact factor: 25.391

9.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.

Authors:  P F Bruning; M J Pit; M de Jong-Bakker; A van den Ende; A Hart; A van Enk
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

10.  A high incidence of vertebral fracture in women with breast cancer.

Authors:  J A Kanis; E V McCloskey; T Powles; A H Paterson; S Ashley; T Spector
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  2 in total

1.  Bone mineral density in estrogen-deficient young women.

Authors:  Vaishali B Popat; Karim A Calis; Vien H Vanderhoof; Giovanni Cizza; James C Reynolds; Nancy Sebring; James F Troendle; Lawrence M Nelson
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

2.  A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy.

Authors:  Elodie Chartron; Nelly Firmin; Célia Touraine; Angélique Chapelle; Eric Legouffe; Lobna Rifai; Stéphane Pouderoux; Lise Roca; Véronique D'Hondt; William Jacot
Journal:  Nutrients       Date:  2021-12-10       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.